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Abbreviations
and Acronyms
AF = atrial ﬁbrillation
CI = conﬁdence interval
CMR = cardiac magnetic
resonance
ECG = electrocardiogram
HR = hazard ratio
LA = left atrium
LVH = left ventricular
hypertrophy
LVM = left ventricular mass
Chrispin et al. JACC Vol. 63, No. 19, 2014
ECG and Imaging Surrogates of LVH With Incident AF May 20, 2014:2007–13
2008surgery, the burden of AF will
likely increase. Importantly, up to
1 of 6 individuals over 40 years of
age will develop AF in the ab-
sence of heart failure or myocar-
dial infarction (5). Known risk
factors associated with the devel-
opment of AF include advanced
age, hypertension, diabetes, myo-
cardial infarction, congestive heart
failure, and valvular heart disease
(2,3,5). Analysis in the Niigata
PreventiveMedicine Study showed
electrocardiographic (ECG) leftventricular hypertrophy ([LVH], deﬁned by Minnesota code
3.1/3.3), ST-T wave abnormalities with left ventricular hyper-
trophy, and premature complexes are also associated with
increased risk for AF (6).
A number of studies have evaluated the predictive ability
of echocardiographic measurements as risk factors for the
development of AF. Such predictive measures include left
atrial enlargement, increased ventricular wall thickness, and
decreased left ventricular fractional shortening (2,7–9).
Cardiac magnetic resonance (CMR) provides a more accu-
rate assessment of myocardial size than echocardiography
does (10–13), but the association of CMR ﬁndings with
incident risk of AF has not been explored. We also sought to
deﬁne the association of baseline ECG-deﬁned LVH with
future development of AF, and the extent to which these
associations are mediated by CMR-conﬁrmed hypertrophy.Methods
Study sample. The MESA (Multi-Ethnic Study of
Atherosclerosis) is a prospective, longitudinal study initiated
in July 2000, in 6 U.S. centers, to evaluate the presence and
progression of subclinical cardiovascular disease. The study
objectives and design have been previously reported (14).
The MESA study includes 6,814 participants 45 to 84 years
of age without clinically recognized cardiovascular disease
(stroke, myocardial infarction, or coronary heart disease) and
with no history of AF at enrollment. A total of 4,942 par-
ticipants underwent ECG and CMR examinations at
baseline during 2000 to 2002 and are included in the ana-
lysis. Incident AF events were based on MESA-ascertained
hospital-discharge International Classiﬁcation of Diseases-
Ninth Revision codes (427.31) and Centers for Medicare
and Medicaid Services inpatient hospital claims. AF events
that occurred during a hospital stay with coronary artery
bypass surgery or valve replacement surgery were not
counted as incident events.
CMR. The MESA CMR protocol, image analysis, and
inter-reader and intrareader reproducibility have been pre-
viously reported (15). Brieﬂy, base to apex short-axis fast
gradient echo images (slice thickness 6 mm, slice gap 4 mm,
ﬁeld of view 360 to 400 mm, matrix 256  160, ﬂip angle20, echo time 3 to 5 ms, repetition time 8 to 10 ms) were
acquired using 1.5-T CMR scanners (15). Left ventricular
mass (LVM) was measured as the sum of the myocardial area
(the difference between endocardial and epicardial con-
tours) times slice thickness plus image gap in the end-
diastolic phase multiplied by the speciﬁc gravity of the
myocardium (1.05 g/ml) (16). The reproducibility of this
protocol was assessed on 79 participants with a technical
measurement error of 6% and an intraclass correlation coef-
ﬁcient of 0.98. The threshold for CMR LVH was set at
>95th percentile of the MESA population.
The original MESA CMR protocol did not measure
left atrium (LA) size. Using the software cmr42 (Cardiac
MRI Software version 4.1, Circle Cardiovascular Imaging,
Alberta, Canada), the baseline LA volume of all participants
with AF and interpretable CMR images along with a 1:1
matched (age, sex, and race) population were measured.
Measurements were obtained at the end of atrial diastole
(just prior to the opening of the mitral valve) in the long-
axis 2- and 4-chamber cine views. The software then cal-
culated a ﬁnal biplane measurement, which was used in
the analysis.
Electrocardiography. LVH by ECG was assessed using 11
different criteria (Table 1). LVM was estimated from the
ECG based on the model by Rautaharju et al. (27), which
adjusts for weight, race, and sex based on ECG and echo-
cardiographic LVH associations in the multicenter Cardio-
vascular Health Study cohort.
Statistical analyses. Continuous data are presented as a
mean  SD. Categorical data are presented as frequency.
The baseline characteristics and CMR- and ECG-derived
variables were compared among participants with and
without incident AF using the chi-square test and Student
t test where appropriate. Univariable and multivariable
Cox proportional hazards models were used to determine
association with AF. Results are presented as hazard ratios
(HR) with 95% conﬁdence intervals (CI). The multivariable
models adjusted for cardiovascular risk factors (age, sex, race,
body mass index, cigarette smoking status, systolic blood
pressure, diabetes, total cholesterol, high-density lipoprotein
cholesterol, and use of digitalis, antiarrhythmic, antihyper-
tensive, and lipid medications) to examine the association of
LVH as deﬁned by CMR and ECG with incident AF. Each
of the 11 ECG criteria for LVH was independently assessed
for their association with AF. When appropriate, the CMR-
LVH group was compared with the CMR group with
LVM 50th percentile. We also tested for 2-way in-
teractions of LVH (by CMR and ECG) with sex and
ethnicity. Finally, because the original MESA MRI mea-
surement protocols did not measure LA volume, we per-
formed a nested case-control study to assess the potential
mediating effect of LA volume for the relationship of
CMR-LVH with incident AF. We measured LA volume
in all incident cases of AF and in age-, sex-, and ethnicity-
matched cases and controls. LA volume assessment was
done blinded to case-control status. We then used Cox
Table 1 ECG Criteria
Model (Ref. #) Criteria
Sokolow-Lyon voltage (17) SV1 þ RV5/V6 3.5 mV and/or RaVL 1.1 mV
Sex-speciﬁc Cornell voltage (18) SV3 þ RaVL >2.8 mV (for men) and >2.0 mV (for women)
Romhilt-Estes point score (19) Diagnostic 5 points and probable 4 points
Criteria Points
Voltage criteria
R or S wave in limb leads 20 mm 3
S wave in V1 or V2 30 mm 3
R wave in V5 or V6 30 mm 3
ST-T wave abnormality
ST-T vector opposite to QRS complex without digitalis 3
ST-T vector opposite to QRS complex with digitalis 1
Negative terminal P mode in V1 1 mm in depth and 0.04 s
in duration
3
Left axis deviation 2
QRS duration 0.09 s 1
Delayed intrinsicoid deﬂection in V5 or V6 (>0.05 s) 1
Perugia score (20) Positivity of 1 of the following 3 criteria:
SV3 þ RaVL >2.4 mV (men) or >2.0 mV (women), left ventricular
strain, or Romhilt-Estes score 5
Perugia 2 score (21) Positivity of 1 of the following 2 criteria:
SV3 þ RaVL >2.4 mV (men) or >2.0 mV (women), or left ventricular strain
Minnesota code 3.1 (22) RV5/V6 >2.6 mV or RI/II/III/aVF >2 mV or RaVL >1.2 mV
Lewis index (23) [(RI þ SIII)  (RIII þ SI)] >1.7 mV
Framingham-adjusted Cornell voltage (24) men: [RaVLþ SV3þ 0.0174 (age 49)þ 0.191 (BMI 26.5)]2.8mV;
women: [RaVLþ SV3þ 0.0387 (age 50)þ 0.212 (BMI 24.9)]2.0mV
Cornell voltage product (25) ([RaVL þ SV3]  QRS duration) 243,600 mVms
Sokolow-Lyon voltage product (25) (SV1 þ RV5/RV6)  QRS duration 371,000 mVms
Gubner and Ungerleider voltage (26) RI þ SIII 2.2 mV
BMI ¼ body mass index; ECG ¼ electrocardiogram.
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2009proportional hazards models with shared frailty (by match-
ing variable) with time to incident AF as outcome and
CMR-LVH (deﬁned as 95th percentile of the MESA
cohort), systolic blood pressure, and use of antihypertensive
medications as independent variables, followed by the
addition of LA volume to examine the role of LA volume
as a mediator of the association between CMR-LVH
and incident AF. Statistical analyses were performed
using STATA statistical software (version 9.0, College
Station, Texas). A p value <0.05 was considered statistically
signiﬁcant.Results
The total number of MESA participants with CMR-LVM
and ECG measures was 4,942. There were 214 incident AF
events documented during a median follow-up of 2,533 days
(6.9 years).
Participants with AF were more likely to be older, Cau-
casian, male, taller, overweight, have underlying systolic
hypertension, have a history of smoking, and have slightly
lower total cholesterol (Table 2). There were no differences
in the prevalence of diabetes or high-density lipoprotein
levels among participants with or without AF.
Participants with incident AF had signiﬁcantly higher
prevalence of LVH at baseline by 6 of 11 ECG criteria(Sokolow-Lyon, Sokolow-Lyon voltage product, Cornell
voltage product, Perugia score, Perugia 2 score, Romhilt-
Estes score) and CMR-LVH (Table 3). The risk of inci-
dent AF was higher in participants with ECG-LVM
>95th percentile compared with those with LVM <50th
percentile (HR: 2.7, 95% CI: 1.7 to 4.1, p  0.001), but
this association was attenuated and lost its signiﬁcance
after adjustment for traditional cardiovascular risk factors
(Table 4).
Eleven ECG-LVH criteria were analyzed for their asso-
ciation with incident AF in both the unadjusted and
adjusted models (Table 5). Six of the 11 models had a sig-
niﬁcant association in the unadjusted models: Sokolow-
Lyon voltage; Sokolow-Lyon voltage product; Cornell
voltage product; Romhilt-Estes score; Perugia score; and
Perugia 2 score. After adjustment for cardiovascular risk
factors, only 3 of 11 ECG-LVH criteria had signiﬁcant
associations with AF: Sokolow-Lyon voltage; Sokolow-
Lyon voltage product; and Perugia score (HR: 1.57, 95%
CI: 1.06 to 2.32, p ¼ 0.02; HR: 2.24, 95% CI: 1.33 to 3.76,
p ¼ 0.002; HR: 1.71, 95% CI: 1.09 to 2.81, p ¼ 0.03,
respectively) (Table 5). Further analysis adjusting for CMR-
LVH showed Sokolow-Lyon voltage product retained sig-
niﬁcant associations with AF (HR: 1.83, 95% CI: 1.06 to
3.14, p ¼ 0.02). Sokolow-Lyon voltage and Perugia score
did not retain signiﬁcance after adjusting for CMR-LVH.
Table 2





(n ¼ 214) p Value
Age, yrs 61.0  10.0 70.0  7.7 <0.001
Men 2,223 (47.02) 130 (60.8) <0.001
Ethnicity <0.001
Caucasians 1,808 (38.2) 118 (54.1)
Chinese 633 (13.4) 15 (7.0)
African American 1,229 (26.0) 42 (19.6)
Hispanics 1,058 (22.4) 39 (18.2)
Height, cm 166.3  9.9 168.6  10.4 0.0008
Weight, kg 76.9  16.2 80.1  16.5 0.005
Cigarette smoking status 0.041
Never 2,441 (51.8) 96 (45.3)
Former 1,668 (35.4) 93 (43.9)
Current 607 (12.9) 23 (10.9)
Systolic blood pressure,
mm Hg
124.9  21.1 134.8  23.4 <0.001
Diabetes 538 (11.4) 27 (12.6) 0.59
Total cholesterol, mg/dl 194.6  35.5 188.8  32.5 0.02
HDL cholesterol, mg/dl 51.2  15.0 50.0  14.2 0.22
Hypertension medication 1,612 (34.1) 122 (57.3) <0.001
Lipid-lowering medication 742 (15.7) 40 (18.8) 0.22
Any antiarrhythmic drug 20 (0.4) 4 (1.8) 0.003
Digitalis 6 (0.13) 4 (1.9) <0.001
Values are mean  SD or n (%). Bold values are statistically signiﬁcant.
AF ¼ atrial ﬁbrillation; HDL ¼ high-density lipoprotein.
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2010There were no multiplicative interactions with sex
(p ¼ 0.504) or race (p ¼ 0.533).
The risk of incident AF increased with CMR LVM in
both the unadjusted and adjusted models (Table 4). In the
unadjusted and adjusted models, participants with
LVM 95th percentile were more likely to have incident
AF (HR: 2.77, 95% CI: 1.84 to 4.16, p ¼ <0.001; and HR:Table 3
Baseline CMR and ECG-Derived Variables of the




(n ¼ 214) p Value
CMR-LVH 217 (4.6) 28 (13.1) <0.001
Sokolow-Lyon voltage 398 (8.5) 33 (15.7) <0.001
Cornell voltage 170 (3.6) 11 (5.2) 0.22
Framingham-adjusted Cornell
voltage
171 (3.6) 11 (5.2) 0.23
Minnesota code 3.1 247 (5.3) 18 (8.6) 0.04
Lewis index 566 (12.1) 26 (12.4) 0.88
Gubner and Ungerleider 278 (5.9) 18 (8.6) 0.115
Sokolow-Lyon voltage product 155 (3.3) 17 (8.1) <0.001
Cornell voltage product 276 (5.9) 23 (11.0) 0.003
Romhilt-Estes score 4 58 (1.3) 6 (3.1) 0.03
Perugia score 229 (5.3) 19 (10.0) 0.004
Perugia 2 score 215 (4.8) 16 (8.4) 0.026
Values are n (%). Bold values are statistically signiﬁcant.
CMR ¼ cardiac magnetic resonance; LVH ¼ left ventricular hypertrophy; other abbreviations as in
Tables 1 and 2.2.04, 95% CI: 1.15 to 3.62, p¼ 0.01, respectively) than were
those with LVM <50th percentile.
Of 214 participants with AF, 206 had an interpretable
CMR LA volume at baseline. The average baseline LA
volume for participants with AF was 65.63 ml, and the
average LA volume for the matched control group was 56.77
ml. When measurements of LA volume were incorporated
into the conditional (shared frailty) Cox proportional haz-
ards model, the association of CMR-LVH (adjusted for
hypertension medications and systolic blood pressure) with
incident AF was attenuated but statistical signiﬁcance was
preserved (HR: 2.17, 95% CI: 1.42 to 3.31, p < 0.001 to
HR: 1.67, 95% CI: 1.07 to 2.60, p ¼ 0.024).
Discussion
The main ﬁnding of this study is that CMR-deﬁned LVH
in the MESA population is associated with development of
incident AF. Participants with a LVM 95th percentile
were 2 more likely to develop AF in this population. In
addition, we found that LVH deﬁned by certain ECG
criteria can also be predictive of AF, and the Sokolow-Lyon
voltage product ECG criteria retained association with
incident AF independent of CMR-LVH.
CMR. The association of CMR-deﬁned LVH with AF
risk is consistent with previous echocardiographic studies.
Previous echocardiographic studies evaluating LVH with the
development of AF showed a HR of 1.28 (95% CI: 1.03 to
1.6) with each 4-mm incremental increase in septal or
posterior left ventricular wall thickness (7). To the best of
our knowledge, no previous studies have evaluated the as-
sociation of CMR-LVH with the development of AF.
CMR has been shown to be superior to echocardiography in
its multiplanar capabilities, soft tissue resolution, and accu-
racy of measuring LVM and LV volumes. Conﬁrmation of
the association of LVH with AF using this superior imaging
modality reinforces the importance of LVH as a risk factor
for the development of AF. Importantly, the association of
CMR-LVH with incident AF was attenuated when
adjusted for CMR LA volume; however, borderline statis-
tical signiﬁcance was retained. This suggests that some, but
not all, of the association of CMR-LVH with incident AF is
mediated by LA enlargement.
ECG. There are a number of established ECG criteria for
the diagnosis of LVH and recent publications have shown
that ECG-based criteria have a low sensitivity but high
speciﬁcity for magnetic resonance imaging–deﬁned LVH
(28,29). Among the 11 ECG criteria, the 3 that retained a
signiﬁcant association with AF in adjusted models were
the Sokolow-Lyon voltage, Sokolow-Lyon voltage product,
and Perugia score. Importantly, however, the Sokolow-Lyon
voltage product remained predictive of AF even after ad-
justing for CMR-LVH. This suggests that the Sokolow-
Lyon voltage product may be a surrogate of other electrical
or structural features associated with the development of
AF beyond anatomical LVH. Furthermore, previous studies
Table 4 HR and 95% CI for Incident AF by LVM
Measure Model 1* Unadjusted p Value Model 2y Multivariable-Adjusted* p Value
CMR-derived
LVMyz 1.50 (1.34–1.687) <0.001 1.45 (1.23–1.70) <0.001
LVM, intervals
50th percentile 1.00 (reference) 1.00 (reference)
50th–90th percentile 1.33 (0.84–2.10) 0.21 1.23 (0.76–2.00) 0.39
90th–95th percentile 1.55 (0.99–2.43) 0.05 1.29 (0.76–2.20) 0.33
>95th percentile 2.77 (1.84–4.16) <0.001 2.04 (1.15–3.62) 0.015
ECG-derivedz
LVMy 1.33 (1.17–1.52) <0.001 1.01 (0.75–1.36) 0.11
LVM, intervals
50th percentile 1.00 (reference) 1.00 (reference)
50th–90th percentile 1.87 (1.18–2.95) 0.007 1.39 (0.84–2.31) 0.19
90th–95th percentile 1.93 (1.22–3.05) 0.005 0.99 (0.54–1.83) 0.99
>95th percentile 2.67 (1.73–4.12) <0.001 1.31 (0.61–2.81) 0.47
Values are hazard ratio (95% conﬁdence interval). Bold values are statistically signiﬁcant. *Adjusted for cardiovascular risk factors (age, sex, ethnicity, weight, height, systolic blood pressure, diabetes, total
and HDL cholesterol, smoking, and hypertension/lipid/arrhythmia/digitalis medication. yStandardized (centered at 0 and scaled to standard deviation units). zECG-LVM derived from Rautaharju models.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; LVM ¼ left ventricular mass; other abbreviations as in Tables 1 to 3.
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2011analyzed ECG time-voltage product in the assessment of
LVH and found QRS duration to be an independent
predictor of LVH (25,30). This suggests that compared
with the Sokolow-Lyon and Perugia score, the association
with incident AF of the Sokolow-Lyon voltage product
may be due to the inclusion of the QRS duration in its
determination.
Study limitations. First, there were a limited number of
AF events, which may explain why some ECG-LVH def-
initions were not signiﬁcantly associated with AF risk.
Second, the ascertainment of AF was based on U.S. inpa-
tient data. This might have led to underestimation of AF
cases not requiring hospitalization or that were managed
abroad. Additionally, in some cases of asymptomatic AF,
time to incident AF may be overestimated. Third, this study
does not differentiate between cases of paroxysmal,Table 5 HR and 95% CI for Incident AF by ECG-LVH Criteria
ECG Measure Model 1* p Value
Voltage-only criteria
Sokolow-Lyon voltage 1.97 (1.36–2.80) <0.001
Cornell voltage 1.49 (0.81–2.73) 0.19
Framingham-adjusted Cornell voltage 1.48 (0.80–2.72) 0.20
Minnesota code 3.1 1.65 (1.01–2.69) 0.04
Lewis index 1.02 (0.68–1.54) 0.89
Gubner and Ungerleider 1.45 (0.89–2.36) 0.12
Voltage-duration product
Sokolow-Lyon voltage product 2.56 (1.56–4.21) <0.001
Cornell voltage product 1.97 (1.28–3.04) 0.002
Composite criteria
Romhilt-Estes score 4 2.45 (1.08–5.53) 0.03
Perugia score 2.07 (1.28–3.32) 0.003
Perugia 2 score 1.83 (1.10–3.06) 0.020
Values are hazard ratio (95% conﬁdence interval). Bold values are statistically signiﬁcant. Dashes indic
ethnicity, weight, height, systolic blood pressure, diabetes, total and HDL cholesterol, smoking, and hyp
ethnicity, weight, height, systolic blood pressure, diabetes, total and HDL cholesterol, smoking, hyperten
Abbreviations as in Tables 1 to 4.persistent, or permanent AF. Fourth, LA volume was
measured in a subset of the total population. Finally, the
model we used for determination of ECG-LVM was
developed using Caucasian and African American pop-
ulations and adjusted only for those ethnicities. In our
analysis, we combined Chinese and Hispanic patients into
the same group with Caucasians. The assumption was made
that ECG criterion for LVH is similar within those
particular groups, but this may not be appropriate and thus
may have contributed to the lack of association between
ECG-LVM and incident AF.
Conclusions
The ﬁndings of this study demonstrate that LVH by CMR
is associated with future risk of AF in participants withModel 2y p Value Model 3z p Value
1.57 (1.06–2.32) 0.02 1.37 (0.92–2.07) 0.12
1.36 (0.72–2.58) 0.33 d d
1.36 (0.76–2.58) 0.33 d d
1.26 (0.76–2.08) 0.35 d d
0.72 (0.47–1.11) 0.14 d d
1.02 (0.62–1.68) 0.91 d d
2.24 (1.33–3.76) 0.002 1.83 (1.06–3.14) 0.02
1.69 (0.94–2.31) 0.09 d d
1.48 (0.64–3.39) 0.94 d d
1.71 (1.09–2.81) 0.03 1.35 (0.79–2.28) 0.26
1.38 (0.80–2.38) 0.25 d d
ate that data was not available. *Unadjusted. yAdjusted for cardiovascular risk factors (age, sex,
ertension/lipid/arrhythmia/digitalis medication. zAdjusted for cardiovascular risk factors (age, sex,
sion/lipid/arrhythmia/digitalis medication, and CMR-LVH).
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2012no clinically evident underlying cardiovascular disease. The
recent statement from the Working Group on Electrocar-
diographic LVH called for validation of ECG criteria as
prognostic determinants (31). Here we have validated 3
ECG algorithms for LVH as prognostic determinants of
incident AF in a multiethnic population (16,26,28). We
have also demonstrated that 1 algorithm (the Sokolow-Lyon
voltage product) has prognostic value beyond structural
LVH as deﬁned by CMR. Importantly, the Sokolow-Lyon
voltage product and Perugia score are simple ECG measures
of LVH that can be performed at the bedside without the
need for digital acquisition of tracings. Given that most
individuals in the general practice do not have CMR images
to assess for LVH, the previously mentioned ECG criteria
can more widely be used to identify individuals at higher
risk for AF. There has been promising evidence in a number
of secondary analysis in large clinical trials (LIFE [Losartan
Intervention for Endpoint Reduction in Hypertension],
VALUE [Valsartan Antihypertensive Long-Term Use
Evaluation], CHARM [Candesartan in Heart Failure–
Assessment of Reduction in Mortality and Morbidity],
Val-HeFT [Valsartan Heart Failure Trial]), and meta-
analyses suggesting that the role of inhibiting the renin-
angiotensin system in reducing the incidence of AF
(32–38). Inhibition of the renin-angiotensin system has
also been shown to decrease LVM, particularly in indivi-
duals with hypertension. Further research is needed to
analyze preventive strategies for the development of AF in
participants with subclinical cardiovascular disease.Acknowledgments
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